This phase 2 study evaluated the efficacy and safety of bortezomib, pomalidomide, and dexamethasone (VPd) induction for newly diagnosed multiple myeloma (NDMM). Thirty-four transplant-eligible and ineligible patients received four cycles of VPd. The overall response rate was 100%, with 87% achieving ≥VGPR (primary endpoint). Common toxicities included anemia, peripheral neuropathy, and constipation. Patients with ≥VGPR had significantly better 12-month PFS and OS than those with PR. The study suggests VPd is safe and efficacious in NDMM, warranting further phase 3 studies.
